Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32551903.
- Also identified by DOI 10.2214/AJR.19.22404.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
<b>OBJECTIVE.</b> The purpose of this article is to review the utility of <sup>18</sup>F-fluciclovine PET/CT in the evaluation of recurrent prostate cancer. <b>CONCLUSION.</b> Fluorine-18-labeled fluciclovine PET/CT has shown promise in the evaluation of recurrent prostate cancer. Its performance has been superior to that of other imaging modalities. It has had good diagnostic accuracy, especially in the detection of extra-prostatic disease recurrence, and the findings have an impact on treatment planning. Gallium-68-labeled prostate-specific membrane antigen PET/CT has also had excellent performance in the detection of biochemically recurrent prostate cancer with detection rates superior to those of fluciclovine PET/CT.
Medical subject headings
- Carboxylic Acids
- Cyclobutanes
- Neoplasm Recurrence, Local
- Positron Emission Tomography Computed Tomography
- Prostatic Neoplasms